Regeneron Pharmaceuticals, Inc. (REGN) by event type
REGN moves most on coverage initiations — a median of +0.34% at 30 minutes across 36 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the REGN overview →
How REGN reacts across 6 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades 576 of 2,717 | 39 | +0.32% | 64% | +0.18% |
| Analyst downgrades 911 of 2,603 | 37 | +0.14% | 57% | -0.33% |
| Coverage initiations 541 of 2,283 | 36 | +0.34% | 61% | +0.47% |
| Rating reiterations 1,573 of 3,522 | 203 | +0.00% | 50% | +0.13% |
| Price-target raises 1,163 of 1,790 | 71 | -0.05% | 48% | +0.11% |
| Price-target cuts 631 of 1,527 | 68 | +0.02% | 52% | +0.24% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one.
That’s how REGN usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst upgrades → · Analyst downgrades → · Coverage initiations → · Rating reiterations → · Price-target raises → · Price-target cuts → · REGN overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| DexCom, Inc. (DXCM) | 2,000+ | +0.04% | 51% |
| Endo International plc - Ordinary Shares (ENDP) | 2,000+ | 0.00% | 49% |
| Novo Nordisk A/S (NVO) | 1,909 | 0.00% | 50% |
| CELGENE (CELG) | 1,880 | +0.03% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.